Business
CorMedix Inc. Announces Appointment of Chief Financial Officer
BERKELEY HEIGHTS, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and
About this update from Cormedix Inc.
[{"type":"text","content":"BERKELEY HEIGHTS, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has appointed Matt David, M.D. as the Company’s Executive Vice President and Chief Financial Officer. Dr. David will participate in the Company’s Conference Call discussing its First Quarter 2020 financial results and recent corporate developments today at 4:30pm Eastern time.\n “I am pleased that Matt has agreed to join the Company at this most exciting time,” said Khoso Baluch, CorMedix Chief Executive Officer. “With his medical background and his significant experience in healthcare capital markets and strategy, he will fill an important role as we continue our preparations to commercialize Neutrolin, whether on our own or with a strategic or commercial partner.” Dr. David was most recently Head of Strategy at Ovid Therapeutics, a Nasdaq-listed biopharmaceutical company focused on rare neurological diseases. In addition to his recent experience in industry, Dr. David has more than 15 years of experience in finance as a healthcare investment banker and earlier as an equity analyst covering the pharma sector. “I am thrilled to be joining CorMedix at such an exciting time for the Company,” commented Dr. David. “As Neutrolin approaches a potential regulatory approval later this year, the Company will face a range of strategic decisions all aimed at bringing Neutrolin to patients who can benefit from it as expeditiously as possible. I am excited by the prospects of this novel product in the substantial hemodialysis market and look forward to working with the broader CorMedix team.” Dr. David earned his M.D. from NYU School of Medicine and was a surgery resident at Beth Israel Hospital. He received his undergraduate degree in Chemistry from Dartmouth College. About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of ce...